Evofem Biosciences, Inc. - FORM 8-K - EX-99.1 - EXHIBIT 99.1

Attached files

file	filename
8-K - 8-K - Evofem Biosciences, Inc.	evfm8-kcorporatepresentati.htm

Exhibit 99.1 Revolutionizing Women’s Sexual and Reproductive Health Saundra Pelletier, CEO H.C. Wainwright & Co. 22nd Annual Global Investment Conference September 14, 2020 Nasdaq: EVFM For investor discussions only. 1 ©©2019 2020 EvofemEvofem Biosciences,Biosciences, Inc.Inc.

Forward-Looking Statements This presentation contains forward looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 and other federal securities laws. In some cases, you can identify forward looking statements by terms such as “may,” ”will,” “should,” “expect,” “plan,” “aim,” “anticipate,” “strategy,” “objective,” “designed,” “suggest,” “currently,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from those, express or implied, in these forward-looking statements. Factors that may cause differences between current expectations and actual results include, but are not limited to, the following: the rate and degree of market acceptance of Phexxi™ (lactic acid, citric acid and potassium bitartrate) vaginal gel o ™ o Evofem’s ability to successfully commercialize Phexxi and its ability to develop sales and marketing capabilities o Evofem’s ability to maintain and protect its intellectual property o Evofem’s ability to rely on existing cash reserves to fund its current development plans and operations and to raise additional capital when needed Evofem’s reliance on third-party providers, such as third-party manufacturers and clinical research organizations o ™ o the presence or absence of any adverse events or side effects relating to the use of Phexxi and EVO100 o the outcome or success of Evofem’s clinical trials o Evofem’s ability to retain members of its management and other key personnel o general risks to the economy represented by spread of the COVID-19 virus o Evofem’s ability to obtain the necessary regulatory approvals for its product candidates and the timing of such approvals, and, o any other risk factors detailed in Evofem’s filings from time to time with the US Securities and Exchange Commission including, without limitation, the 10-K filed on March 12, 2020, 8-K filed on June 2, 2020 and subsequent filings. The forward looking statements in this presentation represent Evofem’s views only as of the date of this presentation, September 14, 2020, and Evofem expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evofem’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based for any reason, except as required by law, even as new information becomes available or other events occur in the future. All forward- looking statements in this presentation are qualified in their entirety by this cautionary statement. For investor discussions only. 2 ©©2019 2020 EvofemEvofem Biosciences,Biosciences, Inc.Inc.

About Evofem Biosciences A Commercial-Stage Biopharmaceutical Company committed to developing and commercializing innovative products to address unmet needs in women’s sexual and reproductive health First-in-Class1 Experienced Unmet FDA-Approved Execution Need Contraceptive Team 1. Phexxi™ (lactic acid/citric acid/potassium bitartrate). Medi- Span®; June 8, 2020, and First DataBank; June 15, 2020. For investor discussions only. 3 ©©2019 2020 EvofemEvofem Biosciences,Biosciences, Inc.Inc.

Phexxi™ First-in-class Vaginal pH Modulator1 • Maintains vaginal pH level of 3.5 – 4.5 even in the presence of semen 2,3,4,5 • Inhibits sperm motility • Non-hormonal, female- controlled, on-demand vaginal gel with bio-adhesive properties • First contraceptive innovation in decades 1. Phexxi™ (lactic acid/citric acid/potassium bitartrate). Medi-Span®; June 8, 2020, and First DataBank; June 15, 2020. 2. Garg et al. Contraception. 2001;64(1):67-75. 3. Nayak et al. Clin Exp Obstet Gynecol. 2019;46(5):736-742 4. Amaral et al. Contraception. 2004;70(6):492-497. 5. Keller et al. PLOS One.2012;7(10):e46901. For investor discussions only. 5 ©©2019 2020 EvofemEvofem Biosciences,Biosciences, Inc.Inc.

Phexxi™ Now Available Indication: For the prevention of pregnancy in females of reproductive potential for use as an on-demand method of contraception.1 Innovative MOA: pH modulating effect2 Favorable Safety Profile: Only 1.6% discontinuation rate due to AEs Unmet Need – 21 million woman at risk for pregnancy but not using hormonal contraception – they are Beyond Hormones – First non-hormonal, woman controlled, non-invasive, used in the moment prescription drug with three naturally-occurring organic compounds to address women that are Beyond Hormones 1. Phexxi [Prescribing Information] Evofem Biosciences, Inc. San Diego CA, May 2020 2. Demonstrated in in vitro studies For investor discussions only. 6 ©©2019 2020 EvofemEvofem Biosciences,Biosciences, Inc.Inc.

HCPs Recognize the Unmet Need for Prescription Non-Hormonal Options Baseline Post-allocation % % Market Research Oral Contraceptives (Regular, 28-day) 30% 26% Survey Highlights PHEXXI™ n/a 15% Hormonal IUD 12% 11% HCPs lowered allocation Condom 10% 8% for hormonal options Injectable 8% 7% from 74% to 64% Oral Contraceptives (Extended) 8% 7% No contraception used, not trying to 6% 5% become pregnant HCPs suggest >10% of Implant 6% 5% women currently using Non-hormonal IUD 4% 4% oral contraceptives are Vaginal ring 5% 4% potential candidates for Fertility awareness/ NFP/ Withdrawal 4% 3% switching to Phexxi Patch 4% 3% Emergency contraception 1% 1% Diaphragm/ Spermicide/ Cervical cap/ 1% 1% Sponge Other 0% 0% TOTAL 100% 100% Source: KJT Group Phexxi HCP Segmentation Market Research – Q4 2018. n=1,024. Q340 Imagine Product X is now available. How many of your patients would use each method as their primary form of contraception, including Product X? For investor discussions only. 7 ©©2019 2020 EvofemEvofem Biosciences,Biosciences, Inc.Inc.

HCP Omnichannel Strategy A Comprehensive Digital Promotional Programs Model to Drive Brand Awareness Educational Videos ResourcesPatient MOA Video HCP Website Rep Leave Behind Leave Rep For investor discussions only. 8 ©©2019 2020 EvofemEvofem Biosciences,Biosciences, Inc.Inc.

Reaching HCPs with “Best in Class” Sales Team Resourced to be scalable, adaptable, flexible; efficiently designed to support our strategy 70 Women’s Health sales reps and regional managers • Average experience of 15 years in Pharma with 8 of those years being in women’s health o Existing relationships, credibility and access to healthcare providers • Targeting ~3500 accounts and the top12K are the highest prescribing HCPs • Leverage HCP segmentation tool to quickly refine target accounts based on customer response and business opportunities Internal Sales Team (tele-reps) • Engaging ~4,400 accounts, or ~8K HCPs, to sell Phexxi via telesales model to drive additional Phexxi Rxs • Partner = Archer Healthcare For investor discussions only. 10 ©©2019 2020 EvofemEvofem Biosciences,Biosciences, Inc.Inc.

The Time is Right for Phexxi In the US today, there are 21 million women at risk for pregnancy who are NOT using hormonal contraception1 1. Daniels K, Abma JC. Current contraceptive status among women aged 15-49: United States, 2015- 2017. NCHS Data Brief. 2018; 327: 1-14. 1111 ©©2019 2020 EvofemEvofem Biosciences,Biosciences, Inc.Inc.

Strategic and Diverse Media Activation Plan SEARCH ADVOCACY PROGRAMMATIC DISPLAY ENDEMIC DISPLAY LIFESTYLE DISPLAY AUDIO ADS SPONSORED CONTENT POINT OF CARE For investor discussions only. 14 ©©2019 2020 EvofemEvofem Biosciences,Biosciences, Inc.Inc.

Priming the Consumer Market and Amplifying the Brand through Notable Outlets and Influential Voices Ongoing Social Content & Sponsored Content Executive Visibility Social Media Placements Communications Support Influencer Engagement Sexual Satisfaction Poll Pre-Launch Launch Post-Launch (August 20’) (September 20’) (October 20’ – February 21’) Dr. Chambers Celebrity Instagram TV Launch branded Bustle HCP Engagement Series: Phexxi Phexxi Facebook Sponsored Fridays and Instagram Virtual Event Ongoing opportunistic and proactive corporate and executive visibility communications support For investor discussions only. 15 ©©2019 2020 EvofemEvofem Biosciences,Biosciences, Inc.Inc.

Phexxi Concierge Experience: An Innovative Digital Marketing Solution An innovative support program Caters to women at any point in their birth control journey Provides options and easy access to Phexxi Provides information and data about Provides information on our Phexxi needed to make an informed telehealth services and co-pay decision about hormone-free birth control program For investor discussions only. 18 ©©2019 2020 EvofemEvofem Biosciences,Biosciences, Inc.Inc.

The Copay Assistance Program Helps Eligible Patients Access Phexxi Prescriptions • Designed to mitigate coverage gaps that occur while payers are making final coverage decisions • Must have commercial insurance • Pay $0 OOP for first fill • Pay as little as $30 OOP for subsequent fills • Prior authorization support provided Powered by For investor discussions only. 20 ©©2019 2020 EvofemEvofem Biosciences,Biosciences, Inc.Inc.

Mail-order Pharmacy Increases Patient Options Ensures coverage Delivers drugs Provides with prior directly to patients’ prescription support authorization homes services support Partnering with a mail-order pharmacy will give patients more options in the COVID environment For investor discussions only. 21 ©©2019 2020 EvofemEvofem Biosciences,Biosciences, Inc.Inc.

At Launch 55% of All Commercial Lives Covered • Phexxi established in two major drug compendia as the first-and-only “Vaginal pH Modulator”1 • To date no insurer has blocked Phexxi following a clinical review • 55% of all commercial lives at launch (i.e. $0 copay, preferred, and/or non-preferred tier coverage) o Remaining insurers expected to review Phexxi before the end of Q4 1. Phexxi™ (lactic acid/citric acid/potassium bitartrate). Medi-Span®; June 8, 2020, and First DataBank; June 15, 2020. For investor discussions only. 22 ©©2019 2020 EvofemEvofem Biosciences,Biosciences, Inc.Inc.

Women Are Demanding More… HAD ENOUGH WITH HORMONES PREFERS NATURAL / ORGANIC HIGHLY INFORMED IN A COMMITTED RELATIONSHIP AVOIDS LONG-TERM BC OPTIONS RESEARCH + REGULAR HCP VISITS …they are tired of figuring out the only difference between new hormonal contraception options and ones of past is changing the way we deliver the same old hormones. 23 ©©2019 2020 EvofemEvofem Biosciences,Biosciences, Inc.Inc.

EVO100 for Prevention of Chlamydia and Gonorrhea in Women AMPREVENCE Phase 2b Trial: Incidence of C/G Statistically Significant Results Continues to Rise • US Chlamydia: ~1.8 10 9.8% million reported cases1 8 50% Relative Risk Reduction 6 • US Gonorrhea: ~580,000 4.9% million reported cases1 4 78% 3.2% Relative Risk Reduction 2 • WW: ~95 million women 0.7% 2 0 Placebo EVO100 Placebo EVO100 likely to get C/G by 2025 CHLAMYDIA GONORRHEA Primary endpoint Secondary endpoint Sources: 1. US. 2018. Centers for Disease Control and Prevention (2019): 2018 STD Surveillance Report. 2. Chlamydia, gonorrhea, trichomonas and syphilis: global prevalence and incidence estimates. June 6, 2019. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6653813/ EVO100 is investigational and safety and efficacy have not been established. For investor discussions only. 24 ©©2019 2020 EvofemEvofem Biosciences,Biosciences, Inc.Inc.

EVO100 for Prevention of Chlamydia and Gonorrhea in Women: Timeline 2020 Q4 2022 2023 Initiate Pivotal Top-Line Phase 3 Results1 Potential Phase 3 Trial Potential NDA submission2 US Approval • FDA Fast Track designation for prevention of chlamydia in women • FDA QIDP designation for prevention of gonorrhea in women o Potential 5-year regulatory exclusivity extension 1. Assumes timely enrollment 2. Assumes favorable outcomes of the Phase 3 clinical trial For investor discussions only. 25 ©©2019 2020 EvofemEvofem Biosciences,Biosciences, Inc.Inc.

Financial Overview Shares outstanding: 81.3M1 Warrants outstanding: 10.4M2 (weighted average exercise price $4.54) Unrestricted cash of $123.6M at June 30, 2020 • Includes $136M in aggregate gross proceeds from two financing transactions closed in Q2 2020 • Runway into Q2 2021 based on projected expenses; Phexxi revenues provide upside 1. As of July 31, 2020. 2. As of June 30, 2020. For investor discussions only. 26 ©©2019 2020 EvofemEvofem Biosciences,Biosciences, Inc.Inc.

Our Time is Now! pHirst major contraceptive innovation in decades – Non-hormonal, female-controlled, on-demand, vaginal pH modulator gel contraceptive Potential to be first and only FDA- EVO100 approved prescription product for Granted fast-track & prevention of urogenital chlamydia and QIDP designation gonorrhea in women 1. Company estimate. For investor discussions only. 27 ©©2019 2020 EvofemEvofem Biosciences,Biosciences, Inc.Inc.

Phexxi Addressable Market & Peak Revenue Potential US Contraceptive Phexxi Annual Gross Revenue Opportunity 1 Market: 69M Women by Market Segment Primary Targets • 6.0M barrier methods • 2.7M withdrawal 3.5% - 4.5%2 = 340k - 440k users 9.7M Non-Rx • 1.0M periodic abstinence Contraceptive $640M - $825M opportunity Users Primary Targets + 2 31.1M 10.2M • 4.7M no contraceptive, no 2.0% - 3.5% = 200k – 360k users Sterilization, No Contraceptive intercourse 3 months prior $375M - $675M opportunity • 5.5M no contraceptive, other non- had intercourse 3 months targets + 18.0M Rx prior 1.0% - 2.0%2 = 180k – 360k users Contraceptive $340M - $675M opportunity Users Secondary Targets • 8.7M oral contraceptives • 5.5M IUDs • 1.6M implant • 1.4M injectable Phexxi Peak Gross • 0.8M ring or patch Revenue (est.) 3 1. Source: CDC’s NCHS National Survey of Family Growth, 2015–2017 $1.4B - $2.2B 2. Estimated market acquisition percentage in segment 3. Gross value of Phexxi user = $267.50 WAC x 7 annual refills = $1,872.50 For investor discussions only. 28 ©©2019 2020 EvofemEvofem Biosciences,Biosciences, Inc.Inc.

Evofem Biosciences, Inc. - FORM 8-K - EX-99.1 - EXHIBIT 99.1 - September 14, 2020

Attached files

Evofem Biosciences, Inc. Reports